Searched for
ZYPREXA
Patent cliff can turn Indian pharma stocks into investor’s goldminePharma stocks have surged due to a 'Patent Cliff,' where numerous drug patents expire, allowing generic manufacturers, especially in India,...- Indoco Remedies gets USFDA nod for schizophrenia, bipolar disorder treatment drugIn a BSE filing, Indoco Remedies announced receipt of approval for its abbreviated new drug application (ANDA) for Olanzapine Tablets USP i...
- Sun Pharma Q4 PAT seen 12% up at Rs 922 croreIt is likely to report a net profit of Rs 922 crore for quarter ended March 2013, up 12 per cent, as compared to a net profit of Rs 820 cro...
- Dr Reddy’s Q2 PAT seen at Rs 370 croreAccording to analysts, the US markets will be key growth driver and may show 22 – 25 per cent growth in the second quarter.
- Jubilant Life's four medicines get USFDA approvalJubilant Life Sciences said it has received approvals from the US health regulator for 4 products that target CNS and CVS therapeutic areas.
- Indian drug companies like Glenmark, Dr Reddy's, Sun Pharma break into world’s fastest growing listThe club of the fastest growing generic companies in the world is dominated by US companies , led by US-based Sagent Pharma, which witnesse...
- Indian pharma companies like Ranbaxy, Dr Reddy’s & others eye $1bn generic opportunityIn the wake of patent expiries on three blockbuster drugs over the last six-seven months, an opportunity worth nearly $1.3 billion is up fo...
- Dr Reddy's Q4 net profit seen at Rs 448cr, up 34% YoYDr Reddy's Laboratories is expected to report a 34% YoY increase in net profit to Rs 448 crore for the fourth quarter, according to an ET N...
- Sun Pharma gets USFDA nod for generic schizophrenia tabletsSun Pharmaceutical Industries said it has received approval from the US health regulator for its generic Zyprexa Zydis tablets in the Ameri...
- Dr Reddy's Labs: US, domestic business growth augurs wellA limited period generic launch helped drug maker Dr Reddy's Labs post exceptional growth in its US business and boosted its overall perfor...
- Pharma sector to see healthy growth, but not for all companiesThe pharma sector is likely to maintain a healthy revenue growth rate of 20-25% for the quarter ended December 2011.
- Ranbaxy Laboratories launches generic Olanzapine tablets in SpainRanbaxy has received necessary regulatory approvals from the Spanish health authorities to manufacture and market Olanzapine in Spain.
- Stocks to watch: RIL, RComm, Shree Cement, Shree Renuka, Murli Industries, Videocon, PiramalReliance Industries will make its second investment in two months in a large shale gas field in the US.
- Lilly 1Q profit rises on higher sales, flat costsDrugmaker Eli Lilly & Co. said Monday its first-quarter profit rose 24 per cent on a boost in sales of the antidepressant Cymbalta and the ...
- Children's disorders increases sales of US pharma cosSales for children of antipsychotic medicines have exploded, fuelled by a 40-fold increase over nine years in the number of children diagno...
- Eli Lilly Q3 net rises 10% $874mEli Lilly said on Thursday that its profit rose 10% during the third quarter on modest growth by its best-selling drug, the antipsychotic Z...
Load More- Dr Reddy’s Q2 PAT seen at Rs 370 crore
